Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > 90 days

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 25, 2023 9:20am

248 Views

Post# 35513479

RE:RE:RE:90 days

ONCY's de Guttadauro stated that he was working towards having one Big Pharma company take both the mBC and the pancreatic Phase 3 clinical studies through to approval, particularly now that pelareorep is set-up for Accelerated Approval in both indications.

Also Roche has guided that the company was focusing on having Tecentriq to advance the company in the immuno-oncology global market space in 2023 and beyond.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China